Shenzhen Weiguang Biological Products Co Ltd Market Cap ($661.44 Million)
Market Cap & Net Worth: Shenzhen Weiguang Biological Products Co Ltd (002880)
Shenzhen Weiguang Biological Products Co Ltd market cap. Shenzhen Weiguang Biological Products Co Ltd (SHE:002880) has a market capitalization of $661.44 Million (CN¥4.52 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10473 globally and #2758 in its home market, demonstrating a -0.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Weiguang Biological Products Co Ltd's stock price CN¥19.93 by its total outstanding shares 226800000 (226.80 Million). Also see Shenzhen Weiguang Biological Products Co (002880) cash flow conversion for how efficiently the company converts equity into cash flow.
Shenzhen Weiguang Biological Products Co Ltd Market Cap History (2017–2026)
Shenzhen Weiguang Biological Products Co Ltd market cap history from 2017 to 2026. Data shows growth from $823.21 Million to $661.44 Million (2.08% CAGR). Check Shenzhen Weiguang Biological Products Co stock quote for real-time trading data and today's change.
Shenzhen Weiguang Biological Products Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Weiguang Biological Products Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Shenzhen Weiguang Biological Products Co equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.67x
Shenzhen Weiguang Biological Products Co Ltd's market cap is 0.67 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.44x
Shenzhen Weiguang Biological Products Co Ltd's market cap is 3.44 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $823.21 Million | $623.39 Million | $154.75 Million | 1.32x | 5.32x |
| 2018 | $612.16 Million | $687.95 Million | $156.64 Million | 0.89x | 3.91x |
| 2019 | $801.35 Million | $821.47 Million | $171.34 Million | 0.98x | 4.68x |
| 2020 | $1.11 Billion | $904.56 Million | $190.40 Million | 1.23x | 5.83x |
| 2021 | $1.05 Billion | $907.43 Million | $205.44 Million | 1.15x | 5.09x |
| 2022 | $1.04 Billion | $667.93 Million | $117.52 Million | 1.56x | 8.89x |
| 2023 | $1.16 Billion | $1.05 Billion | $218.65 Million | 1.10x | 5.29x |
| 2024 | $896.41 Million | $1.20 Billion | $253.52 Million | 0.75x | 3.54x |
| 2025 | $846.29 Million | $1.27 Billion | $246.32 Million | 0.67x | 3.44x |
Competitor Companies of 002880 by Market Capitalization
Companies near Shenzhen Weiguang Biological Products Co Ltd in the global market cap rankings as of November 5, 2026. Also see Shenzhen Weiguang Biological Products Co assets under control for a full breakdown of the balance sheet.
Key companies related to Shenzhen Weiguang Biological Products Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Shenzhen Weiguang Biological Products Co Ltd (2017–2026)
Market capitalization of Shenzhen Weiguang Biological Products Co Ltd from 2017 to today. Between 2017 and today, Shenzhen Weiguang Biological Products Co Ltd's market cap moved from $823.21 Million to $ 661.44 Million, with a yearly change of 2.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥661.44 Million | -21.84% |
| 2025 | CN¥846.29 Million | -5.59% |
| 2024 | CN¥896.41 Million | -22.57% |
| 2023 | CN¥1.16 Billion | +10.79% |
| 2022 | CN¥1.04 Billion | -0.12% |
| 2021 | CN¥1.05 Billion | -5.75% |
| 2020 | CN¥1.11 Billion | +38.50% |
| 2019 | CN¥801.35 Million | +30.91% |
| 2018 | CN¥612.16 Million | -25.64% |
| 2017 | CN¥823.21 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Shenzhen Weiguang Biological Products Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $661.44 Million USD |
| MoneyControl | $661.44 Million USD |
| MarketWatch | $661.44 Million USD |
| marketcap.company | $661.44 Million USD |
| Reuters | $661.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection fre… Read more